Yuou XIA, Yaoming SONG. Efficacy and safety of drug-eluting balloon dilatation for coronary bifurcation disease in diabetic patients[J]. Journal of Third Military Medical University, 2018, 40(24): 2260-2265.
DOI:
Yuou XIA, Yaoming SONG. Efficacy and safety of drug-eluting balloon dilatation for coronary bifurcation disease in diabetic patients[J]. Journal of Third Military Medical University, 2018, 40(24): 2260-2265. DOI: 10.16016/j.1000-5404.201808097.
Efficacy and safety of drug-eluting balloon dilatation for coronary bifurcation disease in diabetic patients
To evaluate the efficacy and safety of paclitaxel drug-eluting balloon (DEB) dilatation for treatment of coronary bifurcation disease in patients with diabetes mellitus.
Methods
2
This study was conducted among 105 patients with coronary artery bifurcation disease undergoing DEB dilation in our department between May
2016 and July
2017. The patients with and without diabetes were compared for major adverse cardiovascular events (MACE; including angina
acute myocardial infarction
target organ revascularization and cardiogenic death) at 6
9 and 12 months following the intervention. At 12 months after surgery
all the patients underwent selective coronary angiography to detect branch stenosis of the coronary artery.
Results
2
The patients in the diabetic and non-diabetic groups were comparable for gender
age and risk factors of coronary heart disease. Multivariate COX regression model analysis showed no significant correlation between diabetes and MACE at 1 year after the operation (
P
=0.235). Selective coronary angiography at 1 year after the operation showed no significant difference in the number of stenotic coronary artery branches between the 2 groups (
P
>
0.05).
Conclusion
2
Diabetes does not increase the risks of MACE or coronary artery branch restenosis after DEB dilatation
which is safe and effective for intervention of coronary artery bifurcation disease in diabetic patients.
ZHENG L F, HAN Y L, JING Q M, et al. Correlation between type 2 diabetes mellitus and severity of coronary artery stenosis[J]. Chin J Intervent Cardiol, 2012, 20(2): 67-71. DOI: 10.3969/j.issn.1004-8812.2012.02.003.
MESSERLI A, WHAYNE T F JR. Impact of diabetes mellitus on percutaneous coronary intervention outcomes: real-world lessons from a large Chinese single-center registry[J]. Angiology, 2018, 69(9): 749-751. DOI: 10.1177/00033 19717740783.
KIRTANE A J, ELLIS S G, DAWKINS K D, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus[J]. J Am Coll Cardiol, 2008, 51(7): 708-715. DOI: 10.1016/j.jacc.2007.10.035.
LI W Q, CHENG Z Y, WEI M X, et al. Intravascular ultrasound-guided interventional treatment of coronary true bifurcation lesions:a clinical study[J]. J Interv Radiol, 2015, 24(4): 292-295. DOI: 10.3969/j.issn.1008-794X.2015.04.004.
XU Y L, LIU Z J. Drug-eluting balloon in treatment of vascular intervention[J]. Adv Cardiovasc Dis, 2013, 34(3): 408-412. DOI: 10.3969/j.issn.1004-3934.2013.03.030.
Expert Group of Expert Consensus on China Diabetes Prevention and Control. Expert consensus on China diabetes prevention and control[J]. Chin J Prevent Med, 2017, 51 (1): 12. DOI: 10.3760/cma.j.issn.0253-9624.2017.01.004.
YAHAGI K, KOLODGIE F D, LUTTER C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus[J]. Arterioscler Thromb Vasc Biol, 2017, 37(2): 191-204. DOI: 10.1161/ATVBAHA.116.306256.
DAEMEN J, GARCIA-GARCIA H M, KUKREJA N, et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus[J]. Eur Heart J, 2007, 28(1): 26-32. DOI: 10.1093/eurheartj/ehl412.
BOYDEN T F, NALLAMOTHU B K, MOSCUCCI M, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus[J]. Am J Cardiol, 2007, 99(10): 1399-1402. DOI: 10.1016/j.amjcard.2006.12.069.
VAN DYCK C J, HOYMANS V Y, HAINE S, et al. New-generation drug-eluting stents: focus on Xience V everolimus- eluting stent and Resolute zotarolimus-eluting stent[J]. J Interv Cardiol, 2013, 26(3): 278-286. DOI: 10.1111/joic.12028.
DE WAHA A, DIBRA A, KUFNER S, et al. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials[J]. Clin Res Cardiol, 2011, 100(7): 561-570. DOI: 10.1007/s00392-010-0278-8.
QIAN H D, ZHENG R L, LI WZ, et al. Clinical efficacy of double stents in the treatment of coronary artery bifurcation lesions[J]. Med Clin Stud, 2011, 28(8): 1514-1517. DOI: 10.3969/j.issn.1671-7171.2011.08.033.
GIL R J, BIL J, KERN A, et al. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: pooled analysis from two randomized studies[J]. Cardiol J, 2018, 25(3): 308-316. DOI: 10.5603/CJ.a2017.0098.
CLEVER Y P, CREMERS B, KRAUSS B, et al. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells[J]. Euro Intervention, 2011, 7(Suppl K): K32-K42. DOI: 10.4244/EIJV7SKA6.
PICARD F, DOUCET S, ASGAR A W. Contemporary use of drug-coated balloons in coronary artery disease: where are we now[J]. Arch Cardiovasc Dis, 2017, 110(4): 259-272. DOI: 10.1016/j.acvd.2017.01.005.
CHEN Y D, WANG J A, LIU B, et al. Chinese expert consensus on the clinical application of drug coated balloon[J]. Chin J Intervent Cardiol, 2016, 24(2): 61-67. DOI: 10.3969/j.issn.1004-8812.2016.02.001.
KLEBER F X, SCHULZ A, WALISZEWSKI M, et al. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty[J]. Clin Res Cardiol, 2015, 104(3): 217-225. DOI: 10.1007/s00392-014-0775-2.
WONG Y T A, KANG D Y, LEE J B, et al. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial[J]. Am Heart J, 2018, 197: 35-42. DOI: 10.1016/j.ahj.2017.11.008.
LIOU K, JEPSON N, CAO C, et al. Drug-eluting balloon versus second generation drug eluting stents in the treatment of in-stent restenosis: a systematic review and meta-analysis[J]. Heart Lung Circ, 2016, 25(12): 1184-1194. DOI: 10.1016/j.hlc.2016.04.001.
Regulation and mechanism of Gm49394 on islet-β cell apoptosis
Liraglutide ameliorates cerebral ischemic injury in diabetic rats by regulating microglia/macrophage polarization through inhibition of NOX2 expression
Association between visceral adiposity index and outcome of prediabetes: report of 1 064 cases
Change of insulin resistance in impaired fasting glucose patients with hypertension: a follow-up study of 5 years
Clinical analysis of permanent, biodegradable and polymerfree drug eluting stent in treatment of unprotected left main coronary artery disease
Related Author
LIU Dong
ZHAO Qingyuan
YANG Shushu
ZHANG Mengjun
LI Jie
LI Yuhao
WANG Li
WU Yuzhang
Related Institution
Department of Immunology, Faculty of Pharmacy and Laboratory Medicine, Army Medical University (Third Military Medical University)
Department of Laboratory Animal Science, College of Basic Medical Sciences, Faculty of Pharmacy and Laboratory Medicine, Army Medical University (Third Military Medical University)
Department of Pharmaceutical Analysis, Faculty of Pharmacy and Laboratory Medicine, Army Medical University (Third Military Medical University)
Department of Pharmacology, College of Pharmacy, Third Military Medical University
Central Laboratory, South-west Hospital, Third Military Medical University